News | Oncology Diagnostics | June 23, 2016

CT-Based Calculations Improve Accuracy of PET for Cancer Patients

Novel method of measuring lean body mass using computed tomography increases precision of molecular imaging

PET-CT, advanced cancer, lean body mass, LBM, SNMMI 2016 study

June 23, 2016 — Cancer patients often experience significant fluctuations in weight and lean body mass (LBM). Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring LBM takes changes in individual body composition into account for better staging of disease and therapy monitoring, said researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 11-15 in San Diego.

Positron emission tomography (PET) has become a standard of care in cancer patient management. Fluorine-18 fluorodeoxyglucose (F-18 FDG) is a radiotracer that closely resembles the metabolic activity of glucose in cells throughout the body. F-18 FDG emits a signal that is detected by the PET scanner. Image reconstructions of these signals let clinicians know where there are areas of abnormally increased metabolic activity, quantified by standardized uptake values (SUV). Accurate tumor SUVs enable clinicians to assess disease progression, reflected by an increased SUV; stable disease, reflected by no significant changes in SUV; and successful response to therapy, reflected by a decrease in SUV.

Radiotracer tumor SUVs are quantitatively measured using patient weight. However, F-18 FDG is distributed almost exclusively in LBM, not fatty tissue. Current methods of SUV normalization tend to focus on overall weight and may significantly over- or underestimate LBM in cancer patients. For this study, researchers developed a computed tomography (CT) technique that determines patient-specific LBM. This method of SUV normalization, using patient-specific LBM, is termed SULps.

“Patients with advanced cancer tend to lose muscle and may gain fat, and these changes in body composition can significantly modify PET results, independent of the actual metabolic activity of the tumor,” said Alexander McEwan, M.D., principal author of the study from the University of Alberta Edmonton in Alberta, Canada. “Our study shows that CT-derived SULps is a more robust measurement for patients with advanced cancer undergoing PET imaging. If adopted, this simple change in imaging protocol could lead to significantly more effective care for cancer patients.”

Researchers analyzed CT scans in three-month intervals to gauge changes in body composition of patients with advanced cancer. A total of 1,080 intervals of CT were evaluated and just over 50 percent, or 546 intervals, reflected stable LBM. Of this smaller group with stable LBM, 40 percent experienced a decrease in adipose tissue, 35 percent showed no change in adipose tissue, and 25 percent showed an increase in adipose tissue. These changes affect SUV using all calculations except SULps, which accurately reflected metabolic activity via F-18 FDG PET/CT.

More precise PET measurements made with the use of CT data, could increase the accuracy of PET imaging interpretation in ground-breaking clinical trials for new cancer therapies and for more personalized medicine in the clinic.

For more information: www.snmmi.org

Related Content

Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...
Numerical simulation with a heterogeneous mouse

Numerical simulation with a heterogeneous mouse. (a) The geometry of the mouse with major organs near the source, and (b) the surface fluence computed with TIM-OS. Image courtesy of Rensselaer Polytechnic Institute.

News | Oncology Diagnostics | September 20, 2019
If researchers could observe drug delivery and its effect on cancer cells in real time, they would be able to tailor...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...
iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along